Indivior Pharmaceuticals, Inc. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Jack Khattar; PEO total compensation $15.50M; PEO compensation actually paid $23.74M; Other NEO average total compensation $1.53M.
- 2024-12-31: PEO total compensation $12.64M; PEO compensation actually paid $9.24M; Other NEO average total compensation $1.59M.
- 2023-12-31: PEO total compensation $13.28M; PEO compensation actually paid $13.49M; Other NEO average total compensation $1.81M.
- 2022-12-31: PEO total compensation $10.01M; PEO compensation actually paid $11.06M; Other NEO average total compensation $1.17M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Jack Khattar | $15.50M | $23.74M | $1.53M | $2.38M | $197.54 | $124.75 | -$38.60M | Gross Product Sales $1.12B | 2026-04-30 |
| 2024-12-31 | $12.64M | $9.24M | $1.59M | $1.27M | $143.72 | $93.49 | $73.90M | $1.10B | 2026-04-30 | |
| 2023-12-31 | $13.28M | $13.49M | $1.81M | $1.69M | $115.02 | $94.03 | $1.30M | $1.07B | 2026-04-30 | |
| 2022-12-31 | $10.01M | $11.06M | $1.17M | $1.43M | $141.77 | $89.90 | $60.70M | $1.18B | 2026-04-30 | |
| 2021-12-31 | $8.12M | $7.91M | $979.00K | $601.47K | $115.90 | $100.02 | $53.40M | $1.02B | 2026-04-30 | |
| 2024-12-31 | Jack Khattar | $17.85M | $14.45M | $2.00M | $1.69M | $152.45 | $118.20 | $73.90M | Gross Product Sales $1.10B | 2025-04-30 |
| 2023-12-31 | $13.28M | $13.49M | $1.81M | $1.69M | $122.01 | $118.87 | $1.30M | $1.07B | 2025-04-30 | |
| 2022-12-31 | $10.01M | $11.06M | $1.17M | $1.43M | $150.38 | $113.65 | $60.70M | $1.18B | 2025-04-30 | |
| 2021-12-31 | $8.12M | $7.91M | $979.00K | $601.47K | $122.93 | $126.45 | $53.40M | $1.02B | 2025-04-30 | |
| 2020-12-31 | $6.67M | $6.13M | $1.20M | $939.60K | $106.07 | $126.42 | $127.00M | $951.00M | 2025-04-30 | |
| 2023-12-31 | Jack Khattar | $13.28M | $13.49M | $1.81M | $1.69M | $122.01 | $118.87 | $1.30M | Gross Product Sales $1.07B | 2024-04-29 |
| 2022-12-31 | $10.01M | $11.06M | $1.17M | $1.43M | $150.38 | $113.65 | $60.70M | $1.18B | 2024-04-29 | |
| 2021-12-31 | $8.12M | $7.91M | $979.00K | $601.47K | $122.93 | $126.45 | $53.40M | $1.02B | 2024-04-29 | |
| 2020-12-31 | $6.67M | $6.13M | $1.20M | $939.60K | $106.07 | $126.42 | $127.00M | $951.00M | 2024-04-29 | |
| 2022-12-31 | Jack Khattar | $10.01M | $11.06M | $1.17M | $1.43M | $150.38 | $113.65 | $61.00M | Gross Product Sales $1.18B | 2023-05-01 |
| 2021-12-31 | $8.12M | $7.91M | $979.00K | $601.47K | $122.93 | $126.45 | $53.00M | $1.02B | 2023-05-01 | |
| 2020-12-31 | $6.67M | $6.13M | $1.20M | $939.60K | $106.07 | $126.42 | $127.00M | $951.00M | 2023-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |